CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

55.43 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

37 38 Next >

CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy? ↗

May 20, 2025

Via The Motley Fool

Prediction: This Beaten-Down Stock Could Double in The Next 5 Years ↗

May 18, 2025

Via The Motley Fool

CRSPR Stock Could Be Ready to Deliver on Its Massive Promise

May 16, 2025

CRSPR Therapeutics has ambitious goals for its gene editing technology and may be getting ready to generate the revenue needed to deliver for shareholders

Via MarketBeat

Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics? ↗

May 14, 2025

Via The Motley Fool

2 Biotech Stocks That Are Screaming Buys in May ↗

May 13, 2025

Via The Motley Fool

Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why ↗

February 28, 2025

Via The Motley Fool

Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire? ↗

May 12, 2025

The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR Therapeutics can replicate the success across its promising pipeline.

Via The Motley Fool

3 Monster Stocks to Hold for the Next 10 Years ↗

May 10, 2025

The planets are lining up for these three stocks' underlying companies.

Via The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

May 08, 2025

In a rising market, the iconic growth investor is adding to positions trading well below their earlier highs.

Via The Motley Fool

Topics Artificial Intelligence World Trade

CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst ↗

May 07, 2025

CRISPR reports data showing dose-dependent lipid reduction and strong safety, with plans to present full results in late 2025.

Via Benzinga

Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation ↗

May 07, 2025

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.

Via Benzinga

These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results ↗

May 07, 2025

Via Benzinga

Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

May 07, 2025

Via Benzinga

Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks ↗

May 06, 2025

The company paused a study of a cystic fibrosis treatment, right on the heels of a scrapped type 1 diabetes program.

Via Investor's Business Daily

Topics Government Intellectual Property

Cathie Wood Sells Palantir Shares Worth $2.65 Million Ahead Of Earnings, Doubles Down On This Chip Giant ↗

April 30, 2025

On Wednesday, April 30, 2025, Cathie Wood sold $2.65 million worth of Palantir shares through various ARK ETFs.

Via Benzinga

2 Beaten-Down Stocks With Incredible Upside Potential ↗

April 30, 2025

Via The Motley Fool

5 Monster Stocks -- Such as Coupang -- to Hold for the Next 10 Years ↗

April 20, 2025

Via The Motley Fool

Topics Artificial Intelligence Economy

3 Magnificent Stocks That Could Double or More by 2030 ↗

April 12, 2025

Via The Motley Fool

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? ↗

April 11, 2025

Via The Motley Fool

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street ↗

April 07, 2025

Via The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

April 07, 2025

The iconic growth investor made some interesting moves during Friday's market pullback.

Via The Motley Fool

Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox ↗

April 04, 2025

Via Benzinga

Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March ↗

April 03, 2025

Via The Motley Fool

Topics Bankruptcy Economy World Trade

Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today ↗

March 31, 2025

Via The Motley Fool

Topics Government World Trade

Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns ↗

March 31, 2025

Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies.

Via Investor's Business Daily

The Future of Healthcare: 10 Predictions For The Next Decade

March 27, 2025

The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we...

Via MarketMinute

Topics Artificial Intelligence

2 Beaten-Down Stocks to Buy on the Dip ↗

March 22, 2025

Via The Motley Fool

2 No-Brainer Biotech Stocks to Buy Right Now ↗

March 19, 2025

Via The Motley Fool

Cathie Wood Stands By Tesla's $2,600 Price Target Despite 40% Stock Drop: 'It's Winner Take Most ↗

March 15, 2025

Via Benzinga

Cathie Wood's Ark Invest Continues To Load Up On Tempus AI, Dumps Bitcoin-Focused Block In Tech Meltdown Aftermath ↗

March 11, 2025

On Tuesday, Cathie Wood‘s Ark Invest executed notable trades, including significant activity involving Tempus AI Inc. (NASDAQ:TEM), Block Inc. (NYSE:XYZ), and DraftKings Inc.<

Via Benzinga

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.